Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Other Operating Expenses (2020 - 2024)

Rani Therapeutics Holdings' Other Operating Expenses history spans 2 years, with the latest figure at $3.7 million for Q4 2024.

  • On a quarterly basis, Other Operating Expenses changed N/A to $3.7 million in Q4 2024 year-over-year; TTM through Sep 2025 was $3.7 million, a N/A change, with the full-year FY2024 number at $3.7 million, changed N/A from a year prior.
  • Other Operating Expenses came in at $3.7 million for Q4 2024, up from -$34.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $3.7 million in Q4 2024, with the low at -$34.0 million in Q4 2020.